Lymphoma and Non-Acute Leukemia DRG 842 Reimbursement

Clinical Trials

Trials assessing frontline chemotherapy combination regimens and short-duration chemoimmunotherapy strategies for newly diagnosed lymphoma patients without complications, typically ambulatory or short-stay inpatients; these studies focus on response rates, time to remission, and early toxicity profiles in patients without severe comorbidity (the DRG captures cases without CC/MCC). This research is relevant because optimizing initial inpatient treatment intensity can reduce length of stay and readmission risk, directly impacting hospital reimbursement and care pathways for this relatively lower-acuity lymphoma cohort.
Comparative effectiveness studies evaluating hospitalization-triggered supportive care interventions (for example, standardized febrile neutropenia management pathways, transfusion thresholds, or infection prophylaxis protocols) in non-acute lymphoma and non-acute leukemia populations; these trials enroll patients admitted for disease-related therapy or complications but without major comorbid conditions to compare outcomes like complication rates, resource utilization, and short-term functional recovery. Payers and providers benefit from evidence that identifies which inpatient supportive strategies safely decrease resource use, shorten LOS, and prevent escalation to higher-acuity DRGs.
Post-discharge outcomes and care coordination trials examining transitional care models, outpatient monitoring programs, or early rehabilitation for patients discharged after initial lymphoma or non-acute leukemia hospitalization; these studies target patients who were admitted without major complications and evaluate readmission rates, outpatient chemotherapy adherence, patient-reported outcomes, and cost-effectiveness of follow-up interventions. This area is important for reducing avoidable readmissions and downstream costs, informing bundled payment approaches and quality metrics for the DRG population.

Chemotherapy without Acute Leukemia as Secondary Diagnosis with CC: Inpatient Reimbursement Overview

838-CHEMOTHERAPY-WITH-ACUTE-LEUKEMIA-AS-SECONDARY-DIAGNOSIS-WITH-CC-OR-HIGH-DOSE-CHEMOTHERAPY-AGENT

Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent: Inpatient Reimbursement Overview

844-OTHER-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASTIC-DIAGNOSES-WITH-CC

Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with CC: Inpatient Reimbursement Overview

830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

841-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-CC

Lymphoma and Non-Acute Leukemia with CC: Inpatient Reimbursement Overview

827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

835-ACUTE-LEUKEMIA-WITH-CC

Acute Leukemia with Complication or Comorbidity: Inpatient Reimbursement Overview

821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 27

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Lymphoma and Non-Acute Leukemia without CC/MCC: Inpatient Reimbursement Overview

DRG 842 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes